Monoamine oxidase inhibitors in obsessive-compulsive disorder.
The authors describe the use of monoamine oxidase inhibitors (MAOIs) in eight patients with severe obsessive-compulsive disorder. In four cases, the MAOIs produced rapid and sustained remission of symptoms; no response was seen in four other patients. All patients who responded to MAOIs, but none of the nonresponders, had phobic anxiety and/or panic attacks. Thus, a trial of MAOIs is indicated in obsessive-compulsive disorder, especially when phobic anxiety or panic attacks form part of the clinical picture.
D000328:Adult; D001008:Anxiety Disorders / Q000188:drug therapy / Q000523:psychology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy* / Q000523:psychology; D010200:Panic / Q000187:drug effects; D010624:Phenelzine / Q000627:therapeutic use*; D010698:Phobic Disorders / Q000188:drug therapy / Q000523:psychology; D014191:Tranylcypromine / Q000627:therapeutic use*
D014191:Tranylcypromine; D010624:Phenelzine